BioSpace News Archive

Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial.

NurExone Biologic Inc. is pleased to announce that it has closed a non-brokered private placement (the “ Private Placement ”).

Seraxis’ Manufacturing Suite Completes GMP Quality System Audit Ahead of SR-02 IND Filing and Transplantation of Pancreatic Clusters to Patients With Type 1 Diabetes.

Tevogen Bio Inc and Semper Paratus Acquisition Corporation announced that the Securities and Exchange Commission has declared effective the registration statement on Form S-4 filed by Semper Paratus in connection with Tevogen Bio and Semper Paratus’s previously announced proposed business combination.

Kriya Therapeutics, Inc., (Kriya) today announced its gene therapy program for thyroid eye disease (TED), a debilitating autoimmune condition resulting in proptosis and diplopia, medical terms describing bulging of the eyes and double vision respectively, due to inflammation of the muscles and fat tissue behind the eye.

Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United States has received a notification that the US Food and Drug Administration (“FDA”) has accepted its Biologics License Application (BLA) for DMB-3115, a proposed biosimilar to Stelara® (Ustekinumab), for substantive review.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2023.

Tiziana Life Sciences Ltd. today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024.

Tango Therapeutics, Inc. announced that, effective January 2, 2024, the Compensation Committee of Tango Therapeutics’ Board of Directors granted a non-qualified stock option to purchase 172,500 shares of its common stock and 26,000 restricted stock units to a new employee under Tango Therapeutics’ 2023 Inducement Plan.

Xeris Biopharma Holdings, Inc. announced that on January 2, 2024, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 130,000 shares of its common stock to 18 new employee under Xeris’ Inducement Equity Plan.